Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Judges Scientific - Capital Network: Interim Results

Judges Scientific Plc (LON:JDG) reported strong 1H 2017 results delivering record figures across revenues, adjusted profit before tax, adjusted earnings per share, and dividends. The management expects to meet the current market consensus for FY2017 earnings thanks to ongoing order intake recovery driving organic growth.
Judges Scientific - Capital Network: Interim Results

1H 2017 INTERIM RESULTS


■ Strong demand recovery continued since June 2016

Judges Scientific Plc (LON:JDG) revenues were up 20% to record high £32.7mn for 1H 2017 (14% organic growth) with adj. operating profit increasing 48% to $4.4mn. Organic sales growth was seen across the region except UK with the biggest growth coming from China/Hong Kong (up 40%). Given most of subsidiaries’ business are international, the management expects healthy demand growth from China and relatively stable growth in EU/US to continue regardless of dampened growth in UK post Brexit. The group’s total order intake saw the same geographical pattern with China/Hong Kong posting the strongest growth of 85% Y/Y for the 1H 2017. The organic order book has improved from 11.2 weeks in June 2016 to 14.9 weeks in January 2017 and 16.5 weeks as of 2H 2017. Demand issues at two subsidiaries in 2016 have receded and management are progressing with resolving the production problems at a third business. As a result, the company’s 12M-trailing ROTIC has improved to 17.4% from 15.2% at the end of 2016.

■ New acquisition: Oxford Cryosystems

During 1H 2017, Judges Scientific Plc (LON:JDG) acquired Oxford Cryosystems, a manufacturer of cryogenic cooling systems used for X-Ray crystallography and other applications. Oxford Cryosystems' products are sold to original equipment manufacturers (OEM) for integration into X-ray Diffraction systems or to users in university research laboratories. While the acquisition is immediately earnings accretive, the acquisition is not a near term growth driver and is no different from Judges’ core strategy of long-term buy and build.

■ Solid dividend growth continues along with prudent debt management

Judges announced interim dividend of 10.0p (vs. 9.0p in 2016), which is well in line with the company’s dividend policy and its historical track record. The management reaffirmed that enhancing shareholder return is its priority as long as the business continues scaling up both organically and through acquisitions, hence c.10% p.a. dividend growth in the near term appears realistic in our view. Overall cash flow has improved during the period, and the company successfully lowered the adj. net debt to £5.8mn from £9.9mn at the beginning of the year bringing net debt/ adj. EBITA ratio to below 1x or close to historical average of around 0.5x.

 

■ Valuation suggests more upside

Reflecting positive 1H 2017 results, we slightly revised up our earnings. We now expect the topline to grow 16% Y/Y to £66.5mn for 2017 with adj. operating margin improving to 14.3% and adj. basic EPS increasing to 105.8p (vs. 84.8p in 2016). Our DCF (assuming 10-year sales CAGR 7%, Gross cash flow CAGR 8% and perpetual growth rate 2%) and DDM (assuming 10% dividend growth for next 5 years and 7.7% for perpetuity) derived fair values imply upside of c.25-30% from current price. Judges shares are currently trading at P/S of 1.9x/1.7x and P/E of 19.1x/15.6x on 2017/2018 adjusted earnings.

Full report is available via Capital Network website


Register here to be notified of future JDG Company articles
View full JDG profile View Profile

Judges Scientific Timeline

Related Researches

no_picture_pai.jpg
November 30 2017

WideCells Group PLC ( LON:WDC) was originally set-up in 2012 in Portugal, as a provider of stem cell storage services for the Portuguese and Spanish markets. In 2016 the company was listed on the London Stock Exchange, raising £1.7mln - net of fees, largely used to establish a new research and storage facility in Manchester, UK and to support the ongoing international expansion.

no_picture_pai.jpg
November 02 2017
  • Preventing and treating diseases through the modulation of the microbiome is one of the most exciting frontiers of healthcare, and a fast growing market
  • OptiBiotix Health PLC (LON:OPTI), an innovative life sciences company focused on human microbiome, is rapidly transitioning from product development to the commercial stage with early revenues and commercial deals with major corporates including Tata and DSM
  • Underpinned by a strong scientific rationale and clinical studies, OptiBiotix Health PLC (LON:OPTI) products help managing significant health problems as weight loss, high cholesterol and hypertension
  • OptiBiotix Health PLC (LON:OPTI) commercial push is currently directed towards the rapidly growing consumer health market
  • A rich deal pipeline is likely to translate in material revenue growth (£1mln+) within 12 months

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use